Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate-to-severe ulcerative colitis

BACKGROUND/AIMS: Data on the efficacy and safety of the adalimumab biosimilar Exemptia are limited. METHODS: Patients with moderate-to-severe active steroid-refractory ulcerative colitis (UC) treated at Dayanand Medical College and Hospital, India were offered cyclosporine A, biologicals or biosimil...

Descripción completa

Detalles Bibliográficos
Autores principales: Midha, Vandana, Mahajan, Ramit, Mehta, Varun, Narang, Vikram, Singh, Arshdeep, Kaur, Kirandeep, Sood, Ajit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Association for the Study of Intestinal Diseases 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5797276/
https://www.ncbi.nlm.nih.gov/pubmed/29422802
http://dx.doi.org/10.5217/ir.2018.16.1.83

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5797276/
https://www.ncbi.nlm.nih.gov/pubmed/29422802
http://dx.doi.org/10.5217/ir.2018.16.1.83

Ejemplares similares